The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Withholding Treatment

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Withholding Treatment


Psychiatry related information on Withholding Treatment


High impact information on Withholding Treatment

  • Six months after the cessation of treatment, plasma testosterone levels had returned to normal and the size of the prostate had increased to 99 +/- 5.5 percent of the initial size [11].
  • BAY 57-1293 (N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide), a well-tolerated member of this class of compounds, significantly reduces time to healing, prevents rebound of disease after cessation of treatment and, most importantly, reduces frequency and severity of recurrent disease [12].
  • Cessation of treatment and recovery allowed us to monitor reemergence of these cell types and revealed that FDCs rely on LT-dependent signals to recompact into appropriately positioned tight networks [13].
  • After cessation of treatment with mexiletine the number of sodium channels returned to normal within 12 d [14].
  • Following cessation of treatment, analog II prevented metastatic tumor development for up to a month and tamoxifen, for 3 weeks [15].

Chemical compound and disease context of Withholding Treatment


Biological context of Withholding Treatment


Anatomical context of Withholding Treatment


Associations of Withholding Treatment with chemical compounds


Gene context of Withholding Treatment

  • Animals given IL-6 or IL-3 plus IL-6 were subsequently thrombocytopenic relative to controls on days 7 through 9 following cessation of treatment [36].
  • The suppressive effect of IL-3 was evident throughout the treatment period (8 or 16 days) but was apparently reversible because NK activity returned to control levels within 8 days after cessation of treatment [37].
  • The eight tumors that regressed with the liposome-p53 complex showed no evidence of relapse for 1 month after the cessation of treatment [38].
  • BDNF-induced survival of auditory neurons in vivo: Cessation of treatment leads to accelerated loss of survival effects [39].
  • In gastrin-deficient mice, significant SPEM was still present 14 days after the cessation of treatment [40].

Analytical, diagnostic and therapeutic context of Withholding Treatment


  1. Low-dose chenodiol to prevent gallstone recurrence after dissolution therapy. Marks, J.W., Lan, S.P., Baum, R.A., Habig, R.L., Hanson, R.F., Hersh, T., Hightower, N.C., Hofmann, A.F., Lachin, J.M., Lasser, E.C. Ann. Intern. Med. (1984) [Pubmed]
  2. Molecular cloning and in vivo evaluation of canine granulocyte-macrophage colony-stimulating factor. Nash, R.A., Schuening, F., Appelbaum, F., Hammond, W.P., Boone, T., Morris, C.F., Slichter, S.J., Storb, R. Blood (1991) [Pubmed]
  3. Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Sachs, D., Cunha, F.Q., Poole, S., Ferreira, S.H. Pain (2002) [Pubmed]
  4. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Fischer, S.M., Conti, C.J., Viner, J., Aldaz, C.M., Lubet, R.A. Carcinogenesis (2003) [Pubmed]
  5. Persistent effects of delayed treatment with nefiracetam on the water maze task in rats with sustained cerebral ischemia. Takeo, S., Fukatsu, T., Miyake-Takagi, K., Takagi, N., Niimura, M., Nagakura, A., Ando, T., Tanonaka, K. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  6. Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. Vonvoigtlander, P.F., Losey, E.G., Triezenberg, H.J. J. Pharmacol. Exp. Ther. (1975) [Pubmed]
  7. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Skolnick, P., Layer, R.T., Popik, P., Nowak, G., Paul, I.A., Trullas, R. Pharmacopsychiatry (1996) [Pubmed]
  8. Polysomnographic findings in five adult patients with pituitary insufficiency before and after cessation of human growth hormone replacement therapy. Nolte, W., Rädisch, C., Rodenbeck, A., Wiltfang, J., Hüfner, M. Clin. Endocrinol. (Oxf) (2002) [Pubmed]
  9. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Christiansen, E., Guirguis, W.R., Cox, D., Osterloh, I.H. Int. J. Impot. Res. (2000) [Pubmed]
  10. Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease. Zlatanic, J., Korelitz, B.I., Rajapakse, R., Kim, P.S., Rubin, S.D., Baiocco, P.J., Panagopoulos, G. J. Clin. Gastroenterol. (2003) [Pubmed]
  11. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. Peters, C.A., Walsh, P.C. N. Engl. J. Med. (1987) [Pubmed]
  12. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Kleymann, G., Fischer, R., Betz, U.A., Hendrix, M., Bender, W., Schneider, U., Handke, G., Eckenberg, P., Hewlett, G., Pevzner, V., Baumeister, J., Weber, O., Henninger, K., Keldenich, J., Jensen, A., Kolb, J., Bach, U., Popp, A., Mäben, J., Frappa, I., Haebich, D., Lockhoff, O., Rübsamen-Waigmann, H. Nat. Med. (2002) [Pubmed]
  13. Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway. Gommerman, J.L., Mackay, F., Donskoy, E., Meier, W., Martin, P., Browning, J.L. J. Clin. Invest. (2002) [Pubmed]
  14. Upregulation of the rat cardiac sodium channel by in vivo treatment with a class I antiarrhythmic drug. Taouis, M., Sheldon, R.S., Duff, H.J. J. Clin. Invest. (1991) [Pubmed]
  15. Effects of nonsteroidal antiestrogens, analog II and tamoxifen, on a metastatic transplantable rat mammary tumor. King, M.M., Magarian, R.A., Terao, J., Brueggemann, G.L. J. Natl. Cancer Inst. (1985) [Pubmed]
  16. Peptic ulcer in children: the predominance of gastric ulcers. Nord, K.S., Rossi, T.M., Lebenthal, E. Am. J. Gastroenterol. (1981) [Pubmed]
  17. Different effects of chronic nicotine treatment regimens on body weight and tolerance in the rat. Morgan, M.M., Ellison, G. Psychopharmacology (Berl.) (1987) [Pubmed]
  18. Long-term bone marrow stromal and hemopoietic toxicity to AZT: protective role of heme and IL-1. Abraham, N.G., Chertkov, J.L., Staudinger, R., Jiang, S., Lutton, J.D., Argani, I., Levere, R.D., Kappas, A. Exp. Hematol. (1993) [Pubmed]
  19. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Ho, V.C., Griffiths, C.E., Albrecht, G., Vanaclocha, F., León-Dorantes, G., Atakan, N., Reitamo, S., Ohannesson, A., Mørk, N.J., Clarke, P., Pfister, P., Paul, C. Br. J. Dermatol. (1999) [Pubmed]
  20. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Wakefield, D., McCluskey, P., Penny, R. Arch. Ophthalmol. (1986) [Pubmed]
  21. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. Sverrisdóttir, A., Fornander, T., Jacobsson, H., von Schoultz, E., Rutqvist, L.E. J. Clin. Oncol. (2004) [Pubmed]
  22. Quantitation of herpes simplex virus type 1 shed in preocular tear film of rabbits treated with acyclovir. Green, M.T., Dunkel, E.C., Morris, B.L. Antimicrob. Agents Chemother. (1981) [Pubmed]
  23. Are enterochromaffinlike cell tumours reversible? An experimental study on gastric carcinoids induced in Mastomys by histamine2-receptor blockade. Wängberg, B., Nilsson, O., Theodorsson, E., Modlin, I.M., Dahlström, A., Ahlman, H. Regul. Pept. (1995) [Pubmed]
  24. Effect of inhaled fluticasone propionate on airway responsiveness in treatment-naive individuals--a lesser benefit in females. Convery, R.P., Leitch, D.N., Bromly, C., Ward, R.J., Bartlett, G., Hendrick, D.J. Eur. Respir. J. (2000) [Pubmed]
  25. Recovery of normal testicular ultrastructure and sperm motility after cessation of gossypol treatment in rats. Hoffer, A.P., Lisser, S.P. J. Androl. (1984) [Pubmed]
  26. Lesions to the anterior hypothalamus prevent the melatonin-induced lengthening of delayed implantation. Berria, M., DeSantis, M., Mead, R.A. Endocrinology (1989) [Pubmed]
  27. Chronic estradiol treatment attenuates stiffening, glycoxidation, and permeability in rat carotid arteries. Mullick, A.E., Walsh, B.A., Reiser, K.M., Rutledge, J.C. Am. J. Physiol. Heart Circ. Physiol. (2001) [Pubmed]
  28. Evaluation of the permanent sympathectomy produced by the administration of guanethidine to adult rats. Johnson, E.M., O'Brien, F. J. Pharmacol. Exp. Ther. (1976) [Pubmed]
  29. Reduction in dopamine transporter mRNA after cessation of repeated cocaine administration. Cerruti, C., Pilotte, N.S., Uhl, G., Kuhar, M.J. Brain Res. Mol. Brain Res. (1994) [Pubmed]
  30. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. Senat, M.V., Minoui, S., Multon, O., Fernandez, H., Frydman, R., Ville, Y. British journal of obstetrics and gynaecology. (1998) [Pubmed]
  31. Reversion from zidovudine resistance to sensitivity on cessation of treatment. Land, S., McGavin, K., Birch, C., Lucas, R. Lancet (1991) [Pubmed]
  32. Intractable insomnia after cessation of treatment with thalidomide. Fox, M.R., Harris, A. Gastroenterology (2001) [Pubmed]
  33. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Fisher, B., Brown, A., Wolmark, N., Redmond, C., Wickerham, D.L., Wittliff, J., Dimitrov, N., Legault-Poisson, S., Schipper, H., Prager, D. Ann. Intern. Med. (1987) [Pubmed]
  34. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats. Karashima, T., Zalatnai, A., Schally, A.V. Proc. Natl. Acad. Sci. U.S.A. (1988) [Pubmed]
  35. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Samid, D., Yeh, A., Prasanna, P. Blood (1992) [Pubmed]
  36. Multiple in vivo effects of interleukin-3 and interleukin-6 on murine megakaryocytopoiesis. Carrington, P.A., Hill, R.J., Stenberg, P.E., Levin, J., Corash, L., Schreurs, J., Baker, G., Levin, F.C. Blood (1991) [Pubmed]
  37. Physiology of natural killer cells. In vivo regulation of progenitors by interleukin 3. Kalland, T. J. Immunol. (1987) [Pubmed]
  38. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Lesoon-Wood, L.A., Kim, W.H., Kleinman, H.K., Weintraub, B.D., Mixson, A.J. Hum. Gene Ther. (1995) [Pubmed]
  39. BDNF-induced survival of auditory neurons in vivo: Cessation of treatment leads to accelerated loss of survival effects. Gillespie, L.N., Clark, G.M., Bartlett, P.F., Marzella, P.L. J. Neurosci. Res. (2003) [Pubmed]
  40. Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice. Nomura, S., Yamaguchi, H., Ogawa, M., Wang, T.C., Lee, J.R., Goldenring, J.R. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) [Pubmed]
  41. Nondetection of O6-methylguanine in rat DNA following in vivo treatment with large doses of cimetidine alone or in combination with sodium nitrite. Kyrtopoulos, S.A., Hadjiloucas, E., Vrotsou, B. Cancer Res. (1982) [Pubmed]
  42. High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin. Kagaya, H., Kato, M., Komatsu, Y., Mizushima, T., Sukegawa, M., Nishikawa, K., Hokari, K., Takeda, H., Sugiyama, T., Asaka, M. Aliment. Pharmacol. Ther. (2000) [Pubmed]
  43. Effects of diethylstilbestrol and estramustine phosphate (Estracyt) on lymphoid cell populations and mitogen responsiveness in male mice. Haukaas, S.A., Kalland, T. J. Urol. (1982) [Pubmed]
  44. Effects of medroxyprogesterone acetate in obstructive sleep apnea. Rajagopal, K.R., Abbrecht, P.H., Jabbari, B. Chest (1986) [Pubmed]
  45. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report. Kazantsev, G.B., Schwesinger, W.H., Heim-Hall, J. Gastrointest. Endosc. (2002) [Pubmed]
WikiGenes - Universities